Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population
| Autor: | Ling Li, David D. Dore, Najat Ziyadeh, Donnie Funch, Heather Norman, John D. Seeger, Helge Gydesen, Atheline Major-Pedersen, Heidrun Bosch-Traberg, Kathleen Mortimer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Databases Factual Endocrinology Diabetes and Metabolism Population Incretin 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Incretins 03 medical and health sciences symbols.namesake 0302 clinical medicine Endocrinology Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Poisson regression Prospective Studies Prospective cohort study education education.field_of_study Insurance Health Liraglutide business.industry Original Articles Middle Aged medicine.disease Confidence interval United States Pancreatic Neoplasms Pancreatitis Relative risk Acute Disease symbols Acute pancreatitis Original Article Female business medicine.drug |
| Zdroj: | Diabetes, Obesity & Metabolism |
| ISSN: | 1463-1326 1462-8902 |
| Popis: | Aims Both acute pancreatitis (AP) and pancreatic cancer (PC) have been areas of focus for studies of incretin drugs. This 5‐year prospective cohort study aimed to quantify possible associations between liraglutide and risk of AP and PC as compared to other antidiabetic drugs (ADs). Materials and methods Patients initiating liraglutide or other ADs who were enrolled in a US health plan (2010‐2014) were included. Comparisons of AP and PC incidence rates were made between matched cohorts of liraglutide initiators and initiators of other ADs. Adjudicated AP cases and algorithm‐based PC cases were identified. Propensity score‐matched intention‐to‐treat (ITT) and time‐on‐drug (TOD) analyses were completed using Poisson regression. A latency analysis was performed for PC. Results Median follow‐up was 405 days for AP cohorts (9995 liraglutide, 1:1 matched to all comparators) and 503 days for PC cohorts (35 163 liraglutide, 1:1 matched to all comparators). In the primary AP analysis, “current” use of liraglutide was not significantly associated with elevated risk across comparators (all comparators relative risk [RR] = 1.2; 95% confidence interval [CI], 0.6‐2.3). ITT results were similar where, in the primary analysis, no RRs were significantly associated with PC (all comparators RR = 0.7; 95% CI, 0.3‐1.4); latency and TOD analyses did not alter findings. There was no evidence of a dose‐response effect. Conclusions Liraglutide was not associated with an increased risk of AP or PC, although risk estimates were more variable for AP, and numbers of cases for both outcomes were limited because of the rarity of outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text